Specifications tableSubjectMedicine and DentistrySpecific subject areaCardiology and Cardiovascular MedicineType of dataTable\
FigureHow data were acquiredData were retrospectively and prospectively collected. FACS data were acquired using a FACS Calibur (BD). Calculations were conducted with IBM SPSS version 18. Graphics were designed by using IBM SPSS version 18 or Sigma Plot 10.0.Data formatRaw\
AnalyzedParameters for data collectionPatients with symptomatic severe aortic stenosis, undergoing transcutaneous valve replacement, were consecutively enrolled at our departement of cardiology and internal medicine at Technische Universität Dresden, Heart Center Dresden, University Hospital, Germany.Description of data collectionPeripheral venous blood samples were collected from all participants through non-traumatic puncture and minimal stasis into sodium-citrate containing tubes and analysed by flow cytometry within 60 minutes after collection. In total, flow-cytometric quantification analyses measurements by cytometric bead arrays (CBA) or routine laboratory tests were performed in 120 patients before and the days after TAVI.Data source locationInstitution: Technische Universität Dresden, Heart Center Dresden, University Hospital\
City/Town/Region: Dresden\
Country: Germany\
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Value of the data {#sec0001a}
=================

•CD11b-expression on monocytes as sign of enhanced cellular activity on day one after TAVI is associated with early death after TAVI.•Determination of parameters of cellular activity or inflammatory cells, like monocyte subpopulations, help to better understand the mechanism of the SIRS after TAVI•The presented data of an association of monocyte activity to mortality and to parameters of platelet activation and further inflammatory marker could be used for further studies to acquire insight into possible underlying causal pathophysiological mechanism after TAVI.•Parameters, like CD11b expression on monocytes, or IL-8 may disclose a potential use as biomarkers or function as possible therapeutic targets in the future.

1. Data Description {#sec0001}
===================

We present data of 120 symptomatic patients with severe aortic stenosis, who underwent TAVI with a transfemoral approach. We focused on parameters of inflammatory reactions after TAVI, which are suspected to have negative effects for the outcome of the patients.[@bib0002] We also present data on monocyte subpopulations, which could be associated with cardiovascular events [@bib0003], MPAs, as established marker for platelet activation [@bib0004] and CD11b expression as an marker of monocyte activation, which could be already shown in patients with atrial fibrillation [@bib0005] and thrombogenicity [@bib0006].

[Table 1](#tbl0001){ref-type="table"} shows procedural outcomes and mortality at 30 days in dependence of three-month mortality. The data show, that there was only a small number of direct procedure-related complications after TAVI. Within 30 days after TAVI, three strokes occurred in the group with worse outcome compared to one stroke in the survivor group. The distribution of diagnosed post-procedural infections was comparable in both groups. The proportion of patients with increased body temperature in the first two days after TAVI was equally distributed. Among patients, who died within the first three months after TAVI, only two died within the first 30 days after TAVI.Table 1Procedural Outcomes and Mortality at 30 Days in dependence of three-month mortalityTable 1Parametersurvivors after 3 months(n= 105)non-survivors after 3 months(n=15)p ValueBalloon expendable valve (%)10 (9.5)1 (7)0.723Self-expendable valve95 (90.5)14 (93)0.723Device Success (transfemoral)105 (100)14 (93)0.334Residual aortic regurgitation ≥26 (6)4 (27)0.105Residual aortic peak velocity, m/s0.198 ± 0.0480.194 ± 0.0530.751Residual aortic mean gradient, mmHg8.7 ± 4.69.9 ± 5.80.440≥ 38°C on day 1 after TAVI n (%)39 (37)3 (20)0.204≥ 38°C on day 2 after TAVI n (%)23 (22)3 (20)0.542**VARC-2**Myocardial infarction0 (0)0(0)1Stroke1 (1)3 (20)0.006\#Renal Failure3 (3)1 (3)0.507Bleeding25 (23.8)5 (33)0.426Access site complication9 (8.6)1 (7)0.803New pacemaker / ICD32 (30.5)6 (40)0.507Mortality 30d02(13)0.015\#post-procedure infections n (%)28 (27)4 (27)1.0[^1]

In [Table 2](#tbl0002){ref-type="table"}, systemic parameters of inflammation in dependence of three-month mortality in the first days after TAVI were presented. Those who did not survive showed a significant increase in CRP and IL-8, especially the day before TAVI. In contrast, the CRP values in the days after TAVI, in which period SIRS typically occurs [@bib0002], showed no association with early mortality. Only IL-8 on day 1 after TAVI and procalcitonin 3 days after TAVI showed a slight association with early mortality. Neither the number of infections after TAVI nor the procalcitonin values before TAVI and in the first two days after TAVI differed between survivors and died patients. Therefore, we do not assume that SIRS or sepsis directly after TAVI in our patient cohort had a decisive influence on three-month mortality.Table 2Systemic parameters of inflammation in dependence of three-month mortalityTable 2Parametersurvivors after 3 months (n= 105)non-survivors after 3 months (n=15)P Valueleukocytes d0, Gpt/l6.9 (5.9-8.3)7.3 (6.5-8.4)0.387*leukocytes d1, Gpt/l*8.9 (7.4-11.1)8.7 (7.4-9.4)0.396*leukocytes d2, Gpt/l*7.8 (6.6-9.9)8.4 (6.6-10.5)0.882*leukocytes d3, Gpt/l*7.8 (6.4-9.8)8.5 (6.5-10.8)0.378*leukocytes d4, Gpt/l*7.2 (6.1-8.8)7.1 (6.0-9.5)0.979leukocytes d5, Gpt/l6.8 (5.6-8.5)8.1 (6.1-9.8)0.058*CRP d0, mg/l*3.9 (1.6-6.2)6.8 (5.0-12.5)**0.029\****CRP d1, mg/l*15.6 (9.5-26.9)14.7 (10.8-49.7)0.670*CRP d2, mg/l*59.0 (35.4-84.0)58.0 (41.5-108.5)0.569*CRP d3, mg/l*69.0 (48.2-99.4)78.4 (47.9-112.0)0.570*CRP d4, mg/l*67.3 (38.0-109.0)60.9 (51.6-146.0)0.459*CRP d5, mg/l*53.1 (33.1-100.0)54.2 (35.7-111.5)0.0.640IL-6 d0, ng/l3.2 (1.8 - 5.2)4.6 (3.9 - 9.1)0.083IL-6 d1, ng/l62.0 (40.7-94.1)45.5 (34.0-143.0)0.793IL-6 d3, ng/l40.4 (26.0-65.6)62.3 (40.3-132.0)0.100IL-6 d7, ng/l1.3 (0-10.8)8.1 (0-17.5)0.305IL-8 d0, ng/l5.9 (3.8-8.5)9.8 (7.0-12.3)**0.005\*\***IL-8 d1, ng/l13.6 (9.5-19.2)18.7 (14.2-25.8)**0.026\***IL-8 d7, ng/l13.0 (7.5-18.2)9.4 (8.8-12.0)0.393PCT d0, µg/l0.1 (0.06 - 0.10)0.1 (0.08-0.10)0.231PCT d1, µg/l0.1 (0.10 - 0.16)0.13 (0.10 - 0.31)0.160PCT d2, µg/l0.11 (0.07 - 0.19)0.20 (0.15 - 0.20)0.332PCT d3, µg/l0.1 (0.09 - 0.15)0.18 (0.10 - 0.56)**0.036\***PCT d5, µg/l0.1 (0.09 - 0.18)0.12 (0.10 - 0.25)0.167neutrophils d0, Gpt/l4.2 (3.4 -- 5.5)4.7 (4.1 -- 5.5)0.312neutrophils d1, Gpt/l6.7 (5.4 -- 8.3)7.1 (5.6 -- 7.7)0.374neutrophils d5, Gpt/l4.4 (3.5 -- 6.15.8 (4.6 -- 8.3)0.832lymphocytes d0, Gpt/l1.6 (1.2 -- 1.9)1.6 (1.3 -- 2.2)0.386lymphocytes d1, Gpt/l0.9 (0.7 -- 1.2)0.8 (0.5 -- 1.1)**0.029\***lymphocytes d5, Gpt/l1.1 (0.9-- 1.4)0.8 (0.7 -- 1.4)0.283[^2]

In [Table 3](#tbl0003){ref-type="table"}, parameters of flow cytometry on day 1 after TAVI in dependence of three-month mortality were shown. The MFI of CD16 on monocytes is significantly associated with mortality, whereas the absolute count of MON2 (CD14++/CD16+) is elevated by trend in the group of the non-survivors. In contrast, MON1-monocytes (CD14++/CD16-) showed a significant association with survival, which suggests that the kind of inflammation and the involved monocyte subpopulations rather than the extent of inflammation itself determines the survival. Furthermore, the expression of the active epitope CD11b on monocytes showed a significant association with early dead after TAVI.Table 3Parameters of flow cytometry on day 1 after TAVI in dependence of three-month mortalityTable 3Parametersurvivors after 3 months (n=93)non-survivors after 3 months (n=12)P ValueMon1 cells/µl591 (441-826)422 (346-529)**0.007\*\***Mon2 cells/µl62 (41-100)91 (66-106)0.101Mon3 cells/µl22 (12-40)21 (14-43)0.513MFI CD16 on monocytes22 (17-32)38 (23-46)**0.007\*\***CD11b+ monocytes, cells/µl35 (23-58)54 (18-123)0.514MFI CD11b on monocytes23 (17-39)42 (30-60)**0.007\*\***MPA, cells/µl237 (160-326)206 (153-329)0.481[^3]

In [Table 4](#tbl0004){ref-type="table"}, we present data of flow cytometry on day 7 after TAVI in dependence of three-month mortality. Here, we see an association of Mon2 and of CD11b expression in monocytes with mortality by trend, without reaching level of significance.Table 4Parameters of flow cytometry on day 7 after TAVI in dependence of three-month mortalityTable 4Parametersurvivors after 3 months (n=56)non-survivors after 3 months (n=10)P ValueMon1 cells/µl408 (312-548)510 (461-560)0.058Mon2 cells/µl37 (26-56)57 (33-86)0.111Mon3 cells/µl16 (10-32)31 (18-45)0.058MFI CD16 on monocytes18 (14-24)24 (19-32)0.088CD11b+ monocytes, cells/µl31 (16-56)58 (22-161)0,084MFI CD11b on monocytes24 (15-48)38 (23-51)0.112\
200 (140-306)170 (136-260)0.604[^4]

[Fig. 1](#fig0001){ref-type="fig"} illustrates the significant association of CD11b expression on monocytes before TAVI with early mortality afterwards.Fig. 1The CD11b-expression on monocytes in dependence of three-month survival after TAVIThe mean fluorescence intensity (MFI) of CD11b on monocytes before TAVI in comparison of survivor (n=105) with non-survivor (n=15) three months after TAVI. Data are presented as box and whisker plots. The ends of the whiskers represent the 5th and the 95th percentile. p=0.024Fig. 1

In [Fig. 2](#fig0002){ref-type="fig"} we demonstrate receiver operating characteristic (ROC) curve analyses of the absolute count of Mon2 (left) and the CD11b-expression on monocytes (right) on day before TAVI for predicting three-month mortality after TAVI. For Mon2 the ROC-analyses revealed an area under the curve (AUC) of 0.82 (95% CI 0.73-0.91) for Mon2 monocytes before TAVI in predicting mortality afterwards. Mon2 monocytes above \>50 cells/µl predicted mortality with a sensitivity of 73% and a specificity of 80%. For the CD11b expression on monocytes, the ROC-analyses revealed an odds ratio of 5.0 (95% CI 1.1 -- 22.0, p=0.033) if the average MFI of CD11b-expression on monocytes was above 55.Fig. 2Receiver operating characteristic (ROC) curve analyses of the absolute count of Mon2 (left) and the CD11b-expression on monocytes (right) on day before TAVI for predicting three-month mortality after TAVIAUC indicates area under the curve. The number in parentheses indicates 95% confidence of intervals.Fig. 2

[Fig. 3](#fig0003){ref-type="fig"} illustrates the significant correlations, we found between monocyte activation (CD11b expression) and parameters of platelet activation (MPAs), monocyte subpopulation (Mon2 content), systemic inflammatory cytokine (IL-8) on day before TAVI and to a clinical SIRS-parameter (body temperature) on day one after TAVI.Fig. 3Correlation analysis of CD11b-expression on monocytes the day before TAVI with: A, MON2 content on day before TAVI; B, the content of MPAs on day before TAVI; C, IL-8 on day before TAVI; D, the body temperature on day one after TAVI.Mon2, (CD14++/CD16+); MFI, mean fluorescence intensity, MPA, Monocyte platelet Aggregates; IL-8, Interleukin 8. \* p\<0.05, \*\* p\<0.01, \*\*\* p\<0.001.Fig. 3

Individual raw data on procedural outcome and on all measured parameters are listed in a supplementary Excel sheet.

2. Experimental Design, Materials and Methods {#sec0002}
=============================================

In 120 patients with symptomatic aortic stenosis, flow cytometric analyses were performed one day before TAVI, on day one after TAVI and seven days after TAVI. Therefore, peripheral venous blood samples were collected from all the study participants through non-traumatic puncture and minimal stasis into sodium-citrate containing tubes and analyzed by flow cytometry within 60 minutes of collection. In total, flow-cytometric quantification analyses were performed in 120 patients. A few patient data are missing on day 1 and day 7 after TAVI, as can be seen from the corresponding tables. Shortly after, 50 µl blood samples were labeled within 10 min with CD45-FITC, CD14-APC, CD11b-PE and CD41-PE (all antibodies were purchased from Becton Dickinson \[BD\], Oxford, United Kingdom). CD11b-PE and CD41-PE were used in different tubes. As control for the determination of CD11b on monocytes, tubes containing CD45, CD14 but not CD11b (fluorescence minus one) were used. Flow cytometric measurements were performed using the BD FACSCalibur flow cytometer. Monocytes were identified by gating strategies based on CD45-expression and side scatter to select monocytes. The degree of co-expression of CD16 and CD14 on monocytes was determined. Subsets were defined as Mon1: CD14++CD16-- ("classical"), Mon2: CD14++CD16+ ("intermediate"), and Mon3: CD14+CD16+ ("nonclassical") monocytes [@bib0007]. The extent of monocyte activation was determined by quantification of the active epitope of the cell adhesion molecule CD11b (MAC-1). The expression of CD11b was measured as mean fluorescence intensity (MFI). The values of fluorescence minus one (FMO) control were subtracted. The content of MPAs was determined by co-expression of CD41 and CD14 on monocytes. Absolute counts of monocyte subpopulations (in cells per µl) were obtained by calculating the number of monocytes proportional to the number of the count in the standard laboratory blood test. For this dual-platform approach, a separate hematoanalyser was used to obtain total leukocyte counts. Proportions of monocyte subsets were obtained by flow cytometry on the same day. IL-6 and IL-8 were assessed by using the cytometric bead arrays (CBA) [@bib0008], according to the manufacturer\'s instructions. Therefore, blood samples were collected in sodium citrate tubes and plasma prepared by centrifugation at 2000xg for 10 min at 4°. The plasma aliquots were stored at -80°C until assayed. Additionally, C-reactive protein and procalcitonin were measured as part of the routine laboratory tests.
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Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.dib.2020.105798](https://doi.org/10.1016/j.dib.2020.105798){#interref0001a}.

[^1]: TAVI, transcatheter aortic valve implantation, VARC-2, Valve Academic Research Consortium-2, ICD, implantable cardioverter-defibrillator. \# the observed events are less than 5.

[^2]: CRP, C-reactive protein; IL, Interleukin, PCT, Procalcitonin, **\*** p\<0.05, **\*\*** p\<0.01.

[^3]: Mon1 (CD14^++^/CD16^−^), Mon2 (CD14^++^/CD16^+^), Mon3 (CD14^+^/CD16^++^), MFI, mean fluorescence intensity, MPA, Monocyte Platelet Aggregates, \* p\<0.05, \*\* p\<0.01.

[^4]: Mon1 (CD14^++^/CD16^−^), Mon2 (CD14^++^/CD16^+^), Mon3 (CD14^+^/CD16^++^), MFI, mean fluorescence intensity, MPA, Monocyte Platelet Aggregates.
